New formulation of mental health drug tested for similarity to standard treatment

NCT ID NCT06494397

Completed Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a new tablet called VHX-896 works the same as the standard drug iloperidone in 26 adults with schizophrenia or bipolar I disorder. Participants took both versions at different times to compare drug levels in the blood and check for side effects. The goal was to see if VHX-896 could be used as an alternative to iloperidone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VHX-896 (a new formulation of iloperidone)
What this could lead to: If successful, this could show that VHX-896 works the same as iloperidone but may offer a different dosing option for patients.
What could go wrong: This is a small, early-phase study focused on drug levels, not on treating symptoms. It does not prove VHX-896 is better or safer than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar I disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR I DISORDER SCHIZOPHRENIA

Contacts and locations

Locations

Vanda Investigational Site

Los Alamitos, California, 90720, United States
Vanda Investigational Site

Gaithersburg, Maryland, 20877, United States
Vanda Investigational Site

Marlton, New Jersey, 08053, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.